PCM
ATRS

Pointe Capital Management’s Antares Pharma, Inc. ATRS Stock Holding History

Pointe Capital Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,000
Closed -$47K – 143
2019
Q4 		$47K Hold
10,000
– – 0.04% 133
2019
Q3 		$33K Hold
10,000
– – 0.03% 137
2019
Q2 		$33K Hold
10,000
– – 0.03% 147
2019
Q1 		$30K Buy
+10,000
New +$32.4K 0.03% 146

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Pointe Capital Management's ATRS Position: Q1 2020 in Review

Pointe Capital Management sold out of Antares Pharma, Inc. (ATRS) in Q1 2020, closing a stake of 10,000 shares — an estimated $47K sold.

Pointe Capital Management first reported a position in ATRS in Q1 2019 and held it in 4 quarters. The position peaked at $47K in Q4 2019. 154 funds tracked by Wall St. Rank hold ATRS as of Q1 2020.

  • Pointe Capital Management reported no remaining Antares Pharma, Inc. position as of Q1 2020 after selling out during the quarter.
  • Pointe Capital Management sold 10,000 Antares Pharma, Inc. shares in Q1 2020, an estimated $47K.
  • Pointe Capital Management first reported a position in Antares Pharma, Inc. in Q1 2019 and held it in 4 quarters.
  • Pointe Capital Management's Antares Pharma, Inc. position peaked at $47K in Q4 2019.
  • 154 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2020.

Based on Pointe Capital Management's 13F filing for Q1 2020, filed 11 May 2020.